Skip to main content

WuXi XDC Cayman

WuXi XDC Cayman Inc. is a China-based contract research, development, and manufacturing organization (CRDMO) focused on antibody-drug conjugates (ADCs) and bioconjugates. The company provides end-to-end services encompassing payload-linker synthesis, conjugation development, analytical testing, and commercial-scale cGMP manufacturing. Its integrated platforms support global biopharmaceutical partners from early-stage discovery through to clinical and commercial supply. Primary revenue is derived from contract development fees, milestone payments, and commercial manufacturing volume orders. WuXi XDC holds a market-leading global position as a specialized contract provider for complex ADC therapies. The company is headquartered in Wuxi, China, and its shares are listed on the Stock Exchange of Hong Kong.

26 of the funds FundTelligence covers report a position in WuXi XDC Cayman.

Legal name
WuXi XDC Cayman Inc
Sector
Health Care
Country
China
Funds holding it
26

Funds holding WuXi XDC Cayman

Showing the 8 largest of 26 funds holding it.

Loading...